SCHEMBL2006463

SCHEMBL2006463

COc1ncccc1-c1ccc(C(C)N)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 2/20 0.49
PGR P06401 1/20 0.49
ALOX5AP P20292 2/20 0.48
FEN1 P39748 2/20 0.48
LOXL2 Q9Y4K0 1/20 0.46
NAAA Q02083 1/20 0.45
CIT O14578 1/20 0.43
DHODH Q02127 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
BTK Q06187 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
PCSK9 Q8NBP7 1/20 0.41
ALK Q9UM73 1/20 0.40
PTGS2 P35354 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008840 1.00 NR3C1 (0.49) NR3C1PGRALOX5APFEN1LOXL2
SCHEMBL12920023 0.87 NR3C1 (0.51) NR3C1PGRALOX5APFEN1LOXL2
SCHEMBL2006626 0.85 PDE1A (0.43) ALOX5APFEN1CIT
SCHEMBL5239044 0.84 NR3C1 (0.54) NR3C1PGRALOX5APFEN1CIT
SCHEMBL2008608 0.84 NR3C1 (0.54) NR3C1PGRALOX5APFEN1CIT
SCHEMBL2002855 0.80 ALOX5AP (0.42) NR3C1PGRALOX5APFEN1LOXL2
SCHEMBL12864093 0.78 NPC1 (0.55) NR3C1PGRALOX5APFEN1LOXL2
SCHEMBL4056518 0.78 DHODH (0.54) ALOX5APFEN1LOXL2NAAADHODH
SCHEMBL13422264 0.78 DHODH (0.53) ALOX5APFEN1LOXL2NAAADHODH
SCHEMBL29501236 0.78 BTK (0.50) ALOX5APFEN1LOXL2NAAADHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960365-B2 Compounds with medicinal effects due to interaction with the glucocorticoid receptor N.V. ORGANON (NL) 2011-06-14 US disclosed
EP-1965785-A1 COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR N.V. Organon (NL) 2008-09-10 EP disclosed
WO-2007071638-A1 COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR N.V. ORGANON (NL) 2007-06-28 WO disclosed
US-20070149577-A1 Compounds with medicinal effects due to interaction with the glucocorticoid receptor N.V. ORGANON (NL) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149577-A1 Compounds with medicinal effects due to interaction with the glucocorticoid receptor NR3C1, NR3C2, MC2R NR3C1 1/4885PGR 131/4885ALOX5AP 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.